Nextrials, Inc. (www.nextrials.com), a leader in clinical research software and services, today announced a significant upgrade for its flagship electronic data capture and clinical trial management platform, Prism™. In addition to its new, more intuitive user interface, Prism now offers expanded functionality and interoperability with electronic health records from multiple vendors.
Prism users will immediately see improvements to its start page, where researchers can now evaluate project data from multiple studies organized into modules that can be easily collapsed and expanded for review. The “at a glance” statistics roll-up bar gives users fast facts such as enrollment status and data quality metrics. And with Prism’s newly streamlined structure, pop-up windows have been reduced in favor of intuitive layers within the browser, creating a more efficient work environment.
A significant change to Prism is its interoperability with data platforms more traditionally found within the healthcare environment for creating and managing electronic medical records. This gives life science companies many more options for implementing studies using patients and sites that were previously unavailable. Major incentives included in the American Recovery and Reinvestment Act (ARRA) will further promote the adoption of electronic medical records, increasing the number of potential sites that can benefit from Prism’s ability to mine data for clinical trials.
“Nextrials has been a leader in working with organizations such as CDISC and IHE to help facilitate the integration of data capture and management solutions used within clinical trials, such as Prism, with those used in hospitals, clinics and practitioner offices,” said James Rogers, co-founder and CEO of Nextrials. “The goal is to offer clinical trial sponsors access to a broader range of clinical investigators and potential patients. The streamlined data collection also provides efficiencies at the site and faster access to study data, helping sponsors hold the line on R&D costs while improving the drug development timeline.”